A first NZ study looked at the role of Lutetium-177-PSMA I & T in the progression of mCRPC
View fulltext online
Citation:Vyas, Madhusudan. (2022, July). A first NZ Study Looked at the Role of Lutetium-177-PSMA I & T in the Progression of mCRPC. Paper presented at the Auckland/Northland Branch NZIMRT, Auckland University Medical School, Auckland.
Permanent link to Research Bank record:https://hdl.handle.net/10652/5803
OBJECTIVES To assess the efficacy of Lutetium-177-PSMA-I&T therapy to palliate end stage mCRPC To review tolerability and impact on QOL of Lutetium-177- PSMA-I&T therapy